475 related articles for article (PubMed ID: 8728551)
1. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
Invernizzi R; Bramante M; Samanin R
Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
Dawson LA; Nguyen HQ; Smith DL; Schechter LE
J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
[TBL] [Abstract][Full Text] [Related]
3. Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.
Dawson LA; Nguyen HQ; Smith DI; Schechter LE
Br J Pharmacol; 2000 Jun; 130(4):797-804. PubMed ID: 10864885
[TBL] [Abstract][Full Text] [Related]
4. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
Gobert A; Millan MJ
Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
6. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
8. LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat.
Mitchell SN; Greenslade RG; Cooper J
Eur J Pharmacol; 2001 Nov; 432(1):19-27. PubMed ID: 11734183
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors.
Hervás I; Artigas F
Eur J Pharmacol; 1998 Sep; 358(1):9-18. PubMed ID: 9809863
[TBL] [Abstract][Full Text] [Related]
10. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.
Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
Neuroscience; 1999; 93(4):1251-62. PubMed ID: 10501449
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935.
Gobert A; Rivet JM; Cistarelli L; Millan MJ
J Neurochem; 1997 Mar; 68(3):1159-63. PubMed ID: 9048762
[TBL] [Abstract][Full Text] [Related]
13. Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists.
Trillat AC; Malagié I; Mathe-Allainmat M; Anmella MC; Jacquot C; Langlois M; Gardier AM
Eur J Pharmacol; 1998 Sep; 357(2-3):179-84. PubMed ID: 9797034
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex.
Dawson LA; Nguyen HQ
Eur J Pharmacol; 1998 Mar; 345(1):41-6. PubMed ID: 9593592
[TBL] [Abstract][Full Text] [Related]
15. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.
De Vry J; Schreiber R; Melon C; Dalmus M; Jentzsch KR
Eur Neuropsychopharmacol; 2004 Dec; 14(6):487-95. PubMed ID: 15589388
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.
Freo U; Merico A; Ermani M; Ori C
Brain Res; 2010 Jun; 1335():24-34. PubMed ID: 20381465
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
Tordera RM; Monge A; Del Río J; Lasheras B
Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Beyer CE; Boikess S; Luo B; Dawson LA
J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
[TBL] [Abstract][Full Text] [Related]
19. Difference in the in vivo influence of serotonin1A autoreceptors on serotonin release in prefrontal cortex and dorsal hippocampus of the same rat treated with fluoxetine.
Li XM; Perry KW; Wong DT
Chin J Physiol; 1999 Jun; 42(2):53-9. PubMed ID: 10513599
[TBL] [Abstract][Full Text] [Related]
20. The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Rasmussen K; Calligaro DO; Czachura JF; Dreshfield-Ahmad LJ; Evans DC; Hemrick-Luecke SK; Kallman MJ; Kendrick WT; Leander JD; Nelson DL; Overshiner CD; Wainscott DB; Wolff MC; Wong DT; Branchek TA; Zgombick JM; Xu YC
J Pharmacol Exp Ther; 2000 Aug; 294(2):688-700. PubMed ID: 10900249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
